Temporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation
Open Access
Abstract
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patients. In contrast to high-doses antiresorptive therapy, denosumab has a transient effect on the inhibition of the bone remodeling process, suggesting that denosumab-related osteonecrosis is a self-limiting disease, with a high curative potential of surgery when performed after a proper duration of receptor activator of nuclear factor-kB ligand (RANKL) inhibitor suspension. We report the long-term clinical and radiological (Computed Tomography—CT scan) data of a patient affected by secondary osteoporosis (cancer treatment-induced bone loss—CTIBL for metastatic breast cancer) who underwent surgical treatment for stage II denosumab-related osteonecrosis of the upper maxilla 7 months after denosumab suspension. A minimally invasive approach was performed with the extraction of the first right upper molar and debridement of the surrounding alveolar bone. After surgery, the patient was followed up at three-month intervals up to 1 year, and clinical and radiological data (CT scan) were recorded at each follow-up for the early detection of signs of recurrent disease. The mucosal healing remained stable in the long term, with radiological signs of bone remodeling in the post-operative site since the 6-month follow-up. The presented case strengthens the hypothesis that denosumab induces temporary alterations of bone turnover with a predictable curative effect of minimal surgical procedures in cases of denosumab-related osteonecrosis of the jaw.Keywords
This publication has 18 references indexed in Scilit:
- Interventions for managing medication-related osteonecrosis of the jawCochrane Database of Systematic Reviews, 2017
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionThe Lancet Diabetes & Endocrinology, 2017
- Observations following discontinuation of long-term denosumab therapyOsteoporosis International, 2017
- Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic reviewInternational Journal of Oral and Maxillofacial Surgery, 2015
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 UpdateJournal of Oral and Maxillofacial Surgery, 2014
- Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonatesBritish Journal of Oral and Maxillofacial Surgery, 2014
- Epidemiology, Clinical Manifestations, Risk Reduction and Treatment Strategies of Jaw Osteonecrosis in Cancer Patients Exposed to Antiresorptive AgentsFuture Oncology, 2014
- The relationship of denosumab pharmacology and osteonecrosis of the jawsOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012
- Learning from experience. Proposal of a refined definition and staging system for bisphosphonate‐related osteonecrosis of the jaw (BRONJ)Oral Diseases, 2012
- Denosumab and bisphosphonates: Different mechanisms of action and effectsBone, 2011